Merck & Co Inc (MRK)

61.23
1.11 1.85
NYSE : Health Care
Prev Close 60.12
Open 60.50
Day Low/High 60.40 / 61.51
52 Wk Low/High 47.97 / 65.46
Volume 10.49M
Avg Volume 10.82M
Exchange NYSE
Shares Outstanding 2.76B
Market Cap 165.59B
EPS 1.60
P/E Ratio 30.64
Div & Yield 1.88 (3.10%)

Latest News

Intermediate Trade: Merck

Intermediate Trade: Merck

I prefer this MRK bearishly biased, vertical put spread expiring in June.

Updated KEYTRUDA® (pembrolizumab) Data In Small Cell Lung Cancer And Mesothelioma Presented At 17th World Conference On Lung Cancer

Updated KEYTRUDA® (pembrolizumab) Data In Small Cell Lung Cancer And Mesothelioma Presented At 17th World Conference On Lung Cancer

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that updated findings from the phase 1b KEYNOTE-028 study investigating the use of KEYTRUDA ® (pembrolizumab), the company's...

Merck To Participate At The Citi 2016 Global Healthcare Conference

Merck To Participate At The Citi 2016 Global Healthcare Conference

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Dr.

KEYTRUDA® (pembrolizumab) Treatment Results In Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma (cHL) Presented At 58th Annual Meeting Of The American Society Of Hematology

KEYTRUDA® (pembrolizumab) Treatment Results In Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma (cHL) Presented At 58th Annual Meeting Of The American Society Of Hematology

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today updated findings evaluating KEYTRUDA ® (pembrolizumab), the company's anti-PD-1 therapy, in two trials of patients with relapsed or...

Updated KEYTRUDA® (pembrolizumab) Findings In Patients With Relapsed Or Refractory Primary Mediastinal Large B-Cell Lymphoma Presented At 58th Annual Meeting Of The American Society Of Hematology

Updated KEYTRUDA® (pembrolizumab) Findings In Patients With Relapsed Or Refractory Primary Mediastinal Large B-Cell Lymphoma Presented At 58th Annual Meeting Of The American Society Of Hematology

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today study findings demonstrating that KEYTRUDA ® (pembrolizumab), the company's anti-PD-1 therapy, achieved an overall response rate...

Apple, Starbucks, Cisco: Doug Kass' Views

Apple, Starbucks, Cisco: Doug Kass' Views

Doug Kass shares his thoughts on a strange, possibly ominous day, and a 'ludicrous forecast.'

FDA Grants Priority Review To Supplemental Biologics License Application (sBLA) For Merck's KEYTRUDA® (pembrolizumab) In Relapsed Or Refractory Classical Hodgkin Lymphoma

FDA Grants Priority Review To Supplemental Biologics License Application (sBLA) For Merck's KEYTRUDA® (pembrolizumab) In Relapsed Or Refractory Classical Hodgkin Lymphoma

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.

Stocks Mixed as Crude Rally Boosts Energy Shares

Stocks Mixed as Crude Rally Boosts Energy Shares

Stocks turn mixed Wednesday as a rally in crude oil fails to provide an across-the-board lift.

Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield

Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

New KEYTRUDA® (pembrolizumab) Data To Be Presented At 17th World Conference On Lung Cancer Highlight Research Across The Spectrum Of Thoracic Malignancies

New KEYTRUDA® (pembrolizumab) Data To Be Presented At 17th World Conference On Lung Cancer Highlight Research Across The Spectrum Of Thoracic Malignancies

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data investigating the use of KEYTRUDA ® (pembrolizumab), the company's anti-PD-1 therapy, across multiple thoracic...

Healthcare Bill Up for House Vote Wed. Hailed as Game-Changer, Blasted as Pharma Handout

Healthcare Bill Up for House Vote Wed. Hailed as Game-Changer, Blasted as Pharma Handout

There is no shortage of opinions and politics as the House prepares for a vote Nov. 30 on 21st Century Cures Act.

(Photo: Business Wire)

(Photo: Business Wire)

Acclaimed actress and singer Bellamy Young lost her father to lung cancer, and she is now sharing her personal experience as part of Test.

Home Depot, Lowe's, Best Buy: Doug Kass' Views

Home Depot, Lowe's, Best Buy: Doug Kass' Views

Doug Kass shares his thoughts on the Trump world and how large-cap biotechs are doing.

Merck Raises Dividend

We favor AbbVie and Pfizer in pharma sector.

Merck Announces Increased Quarterly Dividend

Merck Announces Increased Quarterly Dividend

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has increased the company's quarterly dividend to $0.

New KEYTRUDA® (pembrolizumab) Data In Blood Cancers To Be Presented At 58th Annual Meeting Of The American Society Of Hematology

New KEYTRUDA® (pembrolizumab) Data In Blood Cancers To Be Presented At 58th Annual Meeting Of The American Society Of Hematology

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data regarding the investigational use of KEYTRUDA ® (pembrolizumab), the company's anti-PD-1 therapy, in patients with a...

Jim Cramer's 'Mad Money' Recap: Focusing on Trump's Impact on This Market

Jim Cramer's 'Mad Money' Recap: Focusing on Trump's Impact on This Market

Welcome back, stock owners. We've missed you, says Jim Cramer.

Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios

Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios

Pharma stocks have bounced back from their prior selloff, but whether they will continue their upward trend under a Donald Trump administration remains unclear.

Follow the 'Smart Money' to These Dividend Stocks

A popular strategy is to piggy-back the purchases revealed in 13F filings.

Merck Foundation Announces $10 Million Initiative To Improve Access To High-Quality Diabetes Care In Vulnerable And Underserved U.S. Communities

Merck Foundation Announces $10 Million Initiative To Improve Access To High-Quality Diabetes Care In Vulnerable And Underserved U.S. Communities

The Merck Foundation (Foundation) announced today the launch of a new initiative, Bridging the Gap: Reducing Disparities in Diabetes Care (Bridging the Gap), to improve access to high-quality diabetes care and reduce...

Here Are 2 Excellent Dividend-Paying Drug Stocks to Buy Right Now

Here Are 2 Excellent Dividend-Paying Drug Stocks to Buy Right Now

Two pharmaceutical companies, Gilead Sciences and Merck, offer some of the best yields in their sector.

Germany's Merck Lifts Full-Year Guidance After Sigma-Aldrich Boosts Sales

Germany's Merck Lifts Full-Year Guidance After Sigma-Aldrich Boosts Sales

Shares in the drugmaker climbed after third-quarter earnings and sales beat expectations.

Merck KGaA, Darmstadt, Germany's Phase IIb ADDRESS II Results Confirm Potential Of Atacicept As A Candidate Therapy For SLE

Merck KGaA, Darmstadt, Germany's Phase IIb ADDRESS II Results Confirm Potential Of Atacicept As A Candidate Therapy For SLE

Data presented at the 2016 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting (Abstract Number: 12L)

SBUX, GE, PFE: Jim Cramer's Views

SBUX, GE, PFE: Jim Cramer's Views

Cramer shares his views on the world of unknowns. Starbucks, General Electric and Pfizer are among the stocks discussed.

SBUX, K, PEP: Jim Cramer's Views

SBUX, K, PEP: Jim Cramer's Views

Cramer shares his views on looking at oil now that the election is over. Starbucks, Kellogg and PepsiCo are among the stocks discussed.

Global Week Ahead: Eurozone GDP and Banker Pow-Wow

Global Week Ahead: Eurozone GDP and Banker Pow-Wow

Deutsche Bank CEO Cryan will take center stage at a Frankfurt conference.